Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy (SPiRiT)

Duke University logo

Duke University

Status and phase

Phase 3


Brain Metastases, Adult
Lung Cancer
Primary Brain Tumor


Drug: Namzaric®
Drug: Placebo

Study type


Funder types




Details and patient eligibility


This study represents a survivorship protocol that focuses on cognition and health-related quality of life (HRQoL) in cancer patients that have received prior brain irradiation. The primary purpose of this study is to assess the feasibility of using a digital symptom tracking application focused on HRQoL and cognition in cancer survivors who received brain irradiation.

Full description

Patients who may participate in the study are cancer survivors who received cranial irradiation for conditions including, but not limited to: primary brain tumors, brain metastases, patients with lung cancer receiving prophylactic brain irradiation, and long-term survivors of pediatric cancers. Patients will use the Noona® Healthcare Mobile PRO Application to identify real time select HRQoL and cognitive symptoms. Patients will be instructed to log symptoms as often as relevant using their own personal devices, as well as be prompted to fill out the Patient-Reported Outcomes Measurement Information System Global Health Screen (PROMIS Global Health-10 and Edmonton Symptom Assessment Scale) during treatment (weeks 9 and 14). Patient engagement with the application will be tracked to determine feasibility.


50 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • Cancer survivors who received cranial irradiation including, but not limited to, primary brain tumor, brain metastases, lung cancer receiving prophylactic brain irradiation, long-term survivors of pediatric cancers
  • Initial radiation must have been completed more than 6 months prior to enrollment. Acceptable radiation therapies include fractionated partial brain irradiation, whole brain irradiation, or stereotactic radiosurgery (for any modality at least a total cumulative dose of 20 Gy) of at least 20 Gy
  • Age ≥ 18 years at the time of entry into the study
  • Karnofsky performance score (KPS) ≥ 70 or Eastern Cooperative Oncology Group (ECOG) grade ≤ 2
  • No imaging evidence of disease progression within 4 months of enrollment
  • Life expectancy > 6 months per treating neuro-oncology providers
  • Access to a smartphone, tablet, or computer with capability to utilize the mobile symptom-tracking application
  • Subject must be fluent in English

Exclusion criteria

1. Active psychiatric illness

Trial design

50 participants in 1 patient group

Noona® mobile healthcare application
All patients will be instructed to report pre-defined, non-life-threatening cognitive symptoms as often as relevant through the Noona® application for 17 weeks.

Trial contacts and locations



Central trial contact

Katherine Peters, MD, PhD; Erin Severance

Data sourced from

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems